41292-66-4

Basic information

• Product Name: 1H-Benzimidazol-5-ol,2-methyl-(9CI)
• Synonyms: 1H-Benzimidazol-5-ol,2-methyl-(9CI);2-Methyl-1H-benzo[d]iMidazol-5-ol;2-Methyl-1H-benzimidazol-5-ol;5-Hydroxy-2-methylbenzimidazole;2-methyl-3H-benzimidazol-5-ol;2-methyl-1H-benzo[d]imidazol-5-ol hydrobromide;2-Methyl-3H-benzoimidazol-5-ol
• CAS NO: 41292-66-4
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.17
• Product Categories: BENZIMIDAZOLE
• Mol File: 41292-66-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 432.2±18.0 °C(Predicted)
• Appearance: /
• Density: 1.349
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 9.36±0.40(Predicted)
• CAS DataBase Reference: 1H-Benzimidazol-5-ol,2-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazol-5-ol,2-methyl-(9CI)(41292-66-4)
• EPA Substance Registry System: 1H-Benzimidazol-5-ol,2-methyl-(9CI)(41292-66-4)

Safety Data

• Hazardous Substances Data: 41292-66-4(Hazardous Substances Data)

Usage

General Description

1H-Benzimidazol-5-ol, 2-methyl-(9CI) is a chemical compound that is classified under the Benzimidazoles category. It is also referred to by its CAS registry number, which is 37052-78-1. Benzimidazoles are heterocyclic aromatic organic compounds which consist of a fusion of benzene and imidazole. The structure of 1H-Benzimidazole is the basis for several important biological compounds such as vitamins and enzymes. The 2-methyl-(9CI) notation indicates a specific structural modification of the compound. As a part of the Benzimidazole group, this compound may have various pharmacological actions, although the specific properties of the 2-methyl-(9CI) variant aren't readily available in the literature.

Upstream product

• 610-81-1 4-hydroxy-2-nitroaniline 
• 64-19-7 acetic acid 
• 4887-81-4 5⁽⁶⁾-methoxy 2-methyl benzimidazole 
• 78-39-7 Triethyl orthoacetate 
• 615-72-5 3,4-diaminophenol 
• 75-36-5 acetyl chloride 

Downstream Products

• 101018-69-3 2-methyl-4-(morpholinomethyl)-5-hydroxybenzimidazole 
• 101018-70-6 2-methyl-4-(dimethylaminomethyl)-5-hydroxybenzimidazole 
• 128728-07-4 2-Methyl-4-(4-nitro-phenylazo)-1H-benzoimidazol-5-ol 
• 128728-06-3 2-Methyl-4-phenylazo-1H-benzoimidazol-5-ol 
• 128728-08-5 4-(5-Hydroxy-2-methyl-1H-benzoimidazol-4-ylazo)-benzenesulfonic acid 
• 127025-81-4 2-methyl-5-hydroxy-4-nitrobenzimidazole 
• 124841-32-3 4-chloro-5-hydroxy-2-methyl-1H-benzo[d]imidazole 

Relevant articles and documents

-

-

QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS

The invention relates to the use of compounds of the formula I: wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NRR (wherein R and R, which may be the same or different, each represents hydrogen or C1-3alkyl), or RX- (wherein X and R are as defined herein; R represents hydrogen, oxo, halogeno, hydroxy, C1-4alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulphonyl, N-C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N-(C1-4alkylsulphonyl)amino, N-(C1-4alkylsulphonyl)-N-(C1-4alkyl)amino, N,N-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group RX (wherein X and R are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

Design, synthesis, and in vitro biological activity of benzimidazole based Factor Xa inhibitors

Inhibitors based on the benzimidazole scaffold showed subnanomolar potency against Factor Xa with 500-1000-fold selectivity against thrombin and 50-100-fold selectivity against trypsin. The 2-substituent on the benzimidazole ring had a strong impact on th